Talk:Gabapentinoid
Add topic| This is the talk page for discussing improvements to the Gabapentinoid article. This is not a forum for general discussion of the subject of the article. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
| This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
Gabapentinoid? I believe this is incorrect, see below...
[edit]As per my understanding of chemistry, as suggested by the discernation of a derivative and structural analogue; would make that of a medication with a similar structure to gabapentinoids the primary criterion...not whether or not they are in terms of pharmacodynamics similar, in terms of mechanism of action. Sic, excluding phenibut from being that of a gabapentinoid; as the only similar feature is the inclusion of the gabba-aminobutryic acid amino group; however, lacks the phenyl group or aromatic heterocyclic compound that GABA reacted with phenylacetic acid is derived from...thus; the primary precursor is GABA and beta-phenyl-gamma-aminobutyric acid is thus, the derivative...reiterating that it is indeed that of a derivative, rather, than that of a gabapentinoid. It could be argued because both phenibut and pregabalin share some similar qualities in terms of mechanism of action and that of the GABA molecule that it could be both...however, which would be the primary quality? The pharmacologist and chemist could argue all day...nature versus nurture?
This is due to the ambiguity of the recent distinction between that of a derivative and structural analog in chemistry and also pharmacology; and was thus coined separate identifying terminologies as a result. Structural analogues are drugs similar in structure, making them just that: analogues; whilst, drugs only similar in mechanism of action would be that of derivatives; derived from a similar compound or derived from a precursor compound by that of a chemical reaction, or thought to act similarly to another compound; i.e., the two separate terms opioid and opiate are used as an example, as an opioid is semi/fully synthetic and only a derivative in terms of sharing a similar mechanism of action per modulating the Mu-Opioid Receptor, to that of an opiate, which does the same, however, is natural to nature in the sense that it is derived from an alkaloid from p. Somniferum.
This is at least my understanding...
KR — Preceding unsigned comment added by 50.49.26.127 (talk) 00:52, 28 January 2016 (UTC)
Possible AI generated paragraph
[edit]Hi -- flagged a section with the AI generated template, as I suspect this 2024 edit is LLM output. Fortunately it's one paragraph but it still needs to be checked for source-text integrity, and there are tone issues too. Gnomingstuff (talk) 17:02, 28 August 2025 (UTC)
- I just cut the paragraph down to one lengthy-ish sentence. The reference was legit, so I left it in. But honestly I would be fine if the paragraph were deleted completely, since it's not exactly WP:DUE; just a single study looking at consumption trends, big deal. It doesn't "highlight" or "underscore" anything "remarkable". LLM template removed from the section. Thanks for pointing this out to us. WeirdNAnnoyed (talk) 16:53, 31 August 2025 (UTC)
Baclofen as a gabapentinoid
[edit]@Psychopharma-apprentice Do you have any WP:MEDRS-compliant source indicating that baclofen is a gabapentinoid? Primary sources alone are not sufficient, although the ones I have seen have not referred to it as a gabapentinoid anyways; rather, they would lump it with the GABA-B receptor agonist and gabapentinoid phenibut. Also, please make sure that drug names are not capitalized; they are not proper nouns. Thanks. Slothwizard (talk) 02:17, 2 October 2026 (UTC)
- Hey! here's what I found, but you may not have access to some of these, and many of these articles full text have been difficult to find,
- Dolphin, A.C., Obermair, G.J. (2022). Regulation of Calcium Channels and Synaptic Function by Auxiliary α2δ Subunits. In: Zamponi, G.W., Weiss, N. (eds) Voltage-Gated Calcium Channels . Springer, Cham. https://doi.org/10.1007/978-3-031-08881-0_5
- Weiss, N., Khanna, R. (2022). Trafficking of Neuronal Calcium Channels. In: Zamponi, G.W., Weiss, N. (eds) Voltage-Gated Calcium Channels . Springer, Cham. https://doi.org/10.1007/978-3-031-08881-0_8
- Ferron, L., Zamponi, G.W. (2022). Voltage-Gated Calcium Channels in the Afferent Pain Pathway. In: Zamponi, G.W., Weiss, N. (eds) Voltage-Gated Calcium Channels . Springer, Cham. https://doi.org/10.1007/978-3-031-08881-0_18
- Carai, M.A.M. (2024). Historical Overview on Baclofen, the Only GABAB Receptor Agonist Approved and Available for Clinical Use. In: Colombo, G. (eds) GABAB Receptor. The Receptors. Humana, Cham. https://doi.org/10.1007/978-3-031-67148-7_3
- Romito, J.W., Romito, B.T. (2024). Baclofen Safety, Toxicity, Withdrawal, and Overdose. In: Colombo, G. (eds) GABAB Receptor. The Receptors. Humana, Cham. https://doi.org/10.1007/978-3-031-67148-7_7
- Agabio, R., Rolland, B., Leggio, L. (2024). Baclofen for the Treatment of Alcohol Use Disorder. In: Colombo, G. (eds) GABAB Receptor. The Receptors. Humana, Cham. https://doi.org/10.1007/978-3-031-67148-7_6
- Badri, H., Smith, J.A. (2024). Baclofen for the Treatment of Cough. In: Colombo, G. (eds) GABAB Receptor. The Receptors. Humana, Cham. https://doi.org/10.1007/978-3-031-67148-7_5
- Bonouvrié, L.A. (2024). Baclofen for the Treatment of Spasticity and Dystonia in Cerebral Palsy. In: Colombo, G. (eds) GABAB Receptor. The Receptors. Humana, Cham. https://doi.org/10.1007/978-3-031-67148-7_4
- Taschenberger, H., Lin, KH., Chang, S. (2013). Presynaptic Ca2+ Influx and Its Modulation at Auditory Calyceal Terminals. In: Stephens, G., Mochida, S. (eds) Modulation of Presynaptic Calcium Channels. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6334-0_9
- Cox, P.J., Stevens, E.B. (2013). Presynaptic Calcium Channels as Drug Targets for Pain. In: Stephens, G., Mochida, S. (eds) Modulation of Presynaptic Calcium Channels. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6334-0_14
- Feldman R, Autry B, Dukes J, et al. A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal. Clin Toxicol (Phila). 2023;61(11):941-951. doi:10.1080/15563650.2023.2285702
- Patt A, Fox H, Wells L, Theobald J, Feldman R. Seizure Occurring During Baclofen Monotherapy for Phenibut Withdrawal. Clin Neuropharmacol. 2023;46(2):79-81. doi:10.1097/WNF.0000000000000542
- Irie T, Yamazaki D, Kikura-Hanajiri R. F-phenibut (β-(4-Fluorophenyl)-GABA), a potent GABAB receptor agonist, activates an outward-rectifying K+ current and suppresses the generation of action potentials in mouse cerebellar Purkinje cells. Eur J Pharmacol. 2020;884:173437. doi:10.1016/j.ejphar.2020.173437 Psychopharma-apprentice (talk) 19:24, 22 October 2026 (UTC)
- Thank you! Unfortunately, I don't have access to any of these journals. I think it would be best to find a source that describes baclofen as a non-negligible ligand of α2δ before definitively categorizing it as a gabapentinoid. All these sources appear to be WP:MEDRS-compliant. Maybe we should ping some users that may have access to these. Slothwizard (talk) 20:13, 22 October 2026 (UTC)
- Pinging @DMacks, @Traumnovelle about whether baclofen is a gabapentinoid. Slothwizard (talk) 20:38, 22 October 2026 (UTC)
- I'm not sure why I was pinged; I don't believe I edited either article.
- Baclofen isn't used in veterinary medicine to my knowledge so I have no formal expertise with this but unambiguously considers it a gabapentoid. Traumnovelle (talk) 23:05, 22 October 2026 (UTC)
- Whoops, I pooled from the wrong article. My bad. Slothwizard (talk) 20:13, 23 October 2026 (UTC)
- Pinging @AlyInWikiWonderland, @Oro Temp, @Gettinglit about whether baclofen is a gabapentinoid. Users edited in Gabapentinoid or Baclofen articles. Slothwizard (talk) 20:26, 23 October 2026 (UTC)
- Thanks for the ping. Baclofen indeed isn't considered to be a gabapentinoid. It's widely understood to act as a potent and selective GABA-B receptor agonist. Gabapentinoid refers to α2δ modulators like gabapentin and pregabalin (as well as phenibut) and baclofen shows very weak affinity for α2δ sites compared to the GABA-B receptor (see second table here). Baclofen is structurally related to gabapentinoids but is unlikely to meaningfully act as one itself. This is in contrast to phenibut, which shows higher affinity for the α2δ sites than for the GABA-B receptor and has been clearly characterized as a dually acting gabapentinoid and GABA-B receptor agonist (see e.g. ). Baclofen itself is likely too potent as a GABA-B receptor agonist to allow for doses that would reach meaningful gabapentinoid activity (compare baclofen doses of 5–15 mg/day versus phenibut doses of 250–1,500 mg/day). So I would disagree with baclofen being added to this page or being described as a gabapentinoid. – AlyInWikiWonderland (talk, contribs) 21:28, 23 October 2026 (UTC)
- Hello, nice to meet you!
- Baclofen is approved to treat Alcohol Use Disorder/AUD in some countries (including in France), and it's maximum recommended dose is 300mg per day, and actually as a medical student, having done several internship (8 weeks per internship in France) in 4 medical departments that use bacloten, namely neurology, pain management, psychiatry, and neuropsychiatric addiction medicine, bacloten, especially for off label uses like neuropathic pain, CRPS, brachial plexus injury-related pain with motion loss/paralysis, nociplastic pain, is typically used at high doses, with 200mg being the least used doses for outpatient settings, and often reach the 300mg which is the maximum recommended dose of French drugs controller, and for inpatient settings (which includes all the 4 units I have been in internship with), often go beyond the 300mg French maximum recommended dose limit.
- I agree with the two of you that baclofen is primarily a GABA-B agonist at low dosages, distinguishing it from other gabapentinoids like gabapentin and pregabalin, but at higher dosages, with GABA-B receptors possible saturation, its α2δ binding may be significant, which is maybe why AUD and off label conditions need higher doses than the FDA Psychopharma-apprentice (talk) 10:29, 25 October 2026 (UTC)
- Now, I think I need baclofen’s GABA-B receptors occupancy first, and then determine how much baclofen is unbound from GABA-B receptors, but I doubt I can find that in a way that is accessible to others Psychopharma-apprentice (talk) 10:32, 25 October 2026 (UTC)
- During my research. I also found many other pharmacological properties for baclofen (allosteric modulator of CXCL12 chemokine receptor CXCR4, baclofen being a LAT1 substrate, adenyl cyclase inhibition, G-protein inward rectifier K (GIRK)/Kir3 activation, which aren't on baclofen's page, I'm now just waiting for finding any established target occupancy data Psychopharma-apprentice (talk) 11:44, 25 October 2026 (UTC)
- Maybe baclofen could have some degree of meaningful gabapentinoid activity at extremely high doses like those you describe. But it also had roughly 5-fold lower affinity for the α2δ sites than phenibut in the study I cited above, with phenibut's typical minimum therapeutic dose being 250 mg. So this still remains quite uncertain to me. As far as I know, baclofen has never been reputably described or characterized as a clinically meaningful gabapentinoid in the scientific literature. To portray it as such on Wikipedia would be WP:OR and would not be allowed under Wikipedia policies. – AlyInWikiWonderland (talk, contribs) 22:35, 27 October 2026 (UTC)
- @AlyInWikiWonderland said it well. Usually, I think it's important to note the structural characteristics of a drug, even if it acts differently than most other drugs in its structural class. For example, tianeptine being described as a tricyclic antidepressant or bupropion as a cathinone. However, from what I can tell, "gabapentinoid" has not been used to denote to a structurally-defined class, and instead relates to the α2δ activity.
- I could see why someone would assume they are defined by a structural characteristic at first glance, though. That is probably from where this misunderstanding arose. Oro Temp (talk) 00:00, 25 October 2026 (UTC)
- Indeed, actually, I’ve seen many conflicting reports on Baclofen’s being -or not- a Gabapentinoid.
- Baclofen was initially thought to have anticonvulsant effects-like other gabapentinoids, namely Gabapentin, Pregabalin, but it was found to have negligible, if any, anticonvulsant properties, unlike other “true » gabapentinoids.
- Actually,, Tolibut and 4-fluorophenibut, aside of acting as GABA-B agonists, I found nothing about binding to α2δ protein, and they are described as being selective over GABA-B receptors so far, and inferring them to be α2δ ligands (based on having a structure similar to Phenibut) seems inappropriate
- Tolibut and 4F-phenibut should arguably be relegated as GABA analogues (and i’ll also add Arbaclofen placarbil) not as a Gabapentinoid Psychopharma-apprentice (talk) 15:38, 5 November 2026 (UTC)
- C-Class pharmacology articles
- Mid-importance pharmacology articles
- WikiProject Pharmacology articles
- C-Class chemicals articles
- Low-importance chemicals articles
- C-Class medicine articles
- Mid-importance medicine articles
- C-Class psychiatry articles
- Unknown-importance psychiatry articles
- Psychiatry task force articles
- All WikiProject Medicine pages
